Premium
Economic burden of chronic obstructive pulmonary disease
Author(s) -
TEO W.S. KELVIN,
TAN WOANSHIN,
CHONG WAIFUNG,
ABISHEGANADEN JOHN,
LEW YIIJEN,
LIM TOWKEANG,
HENG BEEHOON
Publication year - 2012
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/j.1440-1843.2011.02073.x
Subject(s) - medicine , copd , public health , emergency department , emergency medicine , health care , total cost , pulmonary disease , disease burden , disease management , ambulatory care , disease , environmental health , family medicine , medical emergency , population , nursing , parkinson's disease , economics , microeconomics , economic growth
Background and objective: The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009. Methods: Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data‐mart. Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data‐mart. Trends in attributable costs, proportions of costs and health‐care utilization were analyzed across each level of care. A weighted attribution approach was used to allocate costs to each health‐care utilization episode, depending on the relevance of co‐morbidities. Results: The mean total cost was approximately $9.9 million per year. Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year. The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009. Based on the 5‐year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs. On average, 42% of the total cost burden was incurred for the medical management of COPD. The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs. Conclusions: COPD is likely to represent a significant burden to the public health system in most countries. The findings are particularly relevant to understanding the allocation of health‐care resources and informing appropriate cost containment strategies.